MAP2K1 and colorectal carcinoma: Since CSCs are involved in drug resistance and disease recurrence, we evaluated the potential of ralimetinib as a sensitizing agent in chemoresistant CRC-SCs as part of a synergistic approach with currently used chemotherapeutics (CHTs), such as 5-FU, CDDP, CPT-11, or trametinib, a MEK1 inhibitor that is already approved for clinical use (Fig. 6D).